ChromaDex's Yasmeen Nkrumah-Elie Wins Trailblazing Woman Award
Yasmeen Nkrumah-Elie Recognized for Her Impact in Nutrition
ChromaDex Corp. (NASDAQ:CDXC), a leader in nicotinamide adenine dinucleotide (NAD+) research, has announced a significant achievement recognized by industry peers. Yasmeen Nkrumah-Elie, Ph.D., serves as the company’s Global Director of External Research and has recently received the prestigious Trailblazing Woman Award from Radicle Science and the Council for Responsible Nutrition.
The Importance of the Trailblazing Woman Award
The Trailblazing Woman Award celebrates exceptional women who have made profound contributions to the dietary supplement and functional food industries. Dr. Nkrumah-Elie's distinguished career has been marked by her unwavering commitment to scientific advancement, her advocacy for diversity, and her mentorship of aspiring female leaders in the field.
A Message from Dr. Nkrumah-Elie
Upon receiving this honor, Dr. Nkrumah-Elie expressed her heartfelt gratitude, stating, "I am deeply honored to receive the Trailblazing Woman Award. The inspiring women in our industry demonstrate how we can push boundaries together. I am proud to play a role in a sector dedicated to enhancing wellness and global health." Her words reflect the collaborative spirit that drives progress in nutrition science.
Commitment to Advancing Science
In her pivotal role at ChromaDex, Dr. Nkrumah-Elie engages deeply with various scientific and regulatory bodies. She is an active member of the Senior Scientific Advisory Council of CRN and works tirelessly with organizations like Women In Nutraceuticals (WIN) and the American Society for Nutrition. Through speaking engagements and collaborations, she bridges scientific knowledge with public understanding, enhancing nutritional literacy.
Achievements of ChromaDex's External Research Program
Dr. Nkrumah-Elie has adeptly led the ChromaDex External Research Program (CERP), transforming it into an acclaimed initiative that engages in nearly 300 research collaborations globally. Under her direction, CERP has cultivated over 30 published clinical trials and identified numerous intellectual property opportunities, reinforcing its position as a benchmark for industry-academia collaboration.
Industry Recognition
Industry leaders have commended Dr. Nkrumah-Elie's contributions. Andrew Shao, Ph.D., Senior Vice President at ChromaDex, noted the evolution of CERP under her guidance, emphasizing how her leadership has set new standards for research quality and partnerships. Pelin Thorogood, Co-Founder of Radicle Science, highlighted her multifaceted impact beyond mere research, alluding to her role as a mentor and advocate for women in science.
About ChromaDex and Its Mission
ChromaDex Corp. stands as a pillar in advancing the science of healthy aging through NAD+ research. Their dedication is evident in their flagship product, Niagen, a patented nicotinamide riboside. Niagen's efficiency as a NAD+ booster has made it the top choice in the healthy aging supplement market. As people age, maintaining adequate NAD+ levels is crucial for preserving health and vitality.
By adhering to rigorous scientific and safety standards, ChromaDex demonstrates its commitment to transparency and quality in the development of nutritional supplements. They work alongside esteemed research institutions to maximize the benefits of NAD+ for consumers.
Consumer Reach and Future Innovations
Tru Niagen, the consumer-facing brand of Niagen, has become a leading choice in the United States for individuals seeking to improve their health as they age. As a testament to its effectiveness, the product is backed by clinical studies that substantiate its ability to enhance NAD+ levels.
Frequently Asked Questions
Who is Yasmeen Nkrumah-Elie?
Yasmeen Nkrumah-Elie, Ph.D., is the Global Director of External Research at ChromaDex and has been recognized for her contributions to the dietary supplement industry.
What is the Trailblazing Woman Award?
This award honors women who have made exceptional impacts in the dietary supplement and functional food industries, highlighting their leadership and innovation.
What is ChromaDex known for?
ChromaDex is known for its research on nicotinamide adenine dinucleotide (NAD+) and its clinically proven ingredient, Niagen.
What role does Dr. Nkrumah-Elie play at ChromaDex?
She leads the External Research Program and fosters collaborations with various scientific organizations to advance research in nutrition.
Why is NAD+ important for health?
NAD+ is a vital coenzyme found in all human cells. Its levels decline with age, and maintaining adequate NAD+ is essential for supporting overall health and vitality.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.